External Quality Assessment for Thrombin Generation Tests: An Exploration

 

 Buy Article Permissions and Reprints

ABSTRACT

External Quality Control of Diagnostic Assays and Tests (ECAT) surveys on thrombin generation rests (TGTs) have identified that various tests show a more than 30-fold difference in time to peak (TTP). The survey included pooled normal plasmas, microparticle (MP)-depleted plasmas, and factor (F)XII-deficient patient plasma. Between 4 and 11 laboratories participated per test; analyzed were a time (TTP) and quantity variable (AUC). MP depletion of plasma showed a progressive increase in TTP up to 29% with a decreasing tissue factor. The same was found for the AUC with the largest decrease of 38%. It was observed that MP depletion showed large individual differences. The FXII-deficient plasma showed no effect on TTP for rapid tests, but for slow tests it increased from 248 to 331%. The AUC declined gradually the slower the test, reaching a decline of 85%. The effects of FXII deficiency were not mimicked by the addition of corn trypsin inhibitor but were confirmed by inhibiting activated FXI. Interlaboratory variability was between 11% and 57% for all methods, showing differences mainly related to the used normal pooled plasma. The different sensitivities of TGTs to MPs and contact activation predict that they will associate differently with clinical situations, according to which of these aspects are important. Future ECAT surveys should include samples with variation in MPs and contact activation to match with features of the TGT variants.

REFERENCES

• 1 Hemker H C, Giesen P, AlDieri R et al.. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.  Pathophysiol Haemost Thromb. 2002;  32(5–6) 249-253
  CrossrefPubMedGoogle Scholar
• 2 Hron G, Kollars M, Binder B R, Eichinger S, Kyrle P A. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.  JAMA. 2006;  296(4) 397-402
  CrossrefPubMedGoogle Scholar
• 3 Devreese K, Wijns W, Combes I, Van kerckhoven S, Hoylaerts M F. Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis.  Thromb Haemost. 2007;  98(3) 600-613
  PubMedGoogle Scholar
• 4 Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition.  J Thromb Haemost. 2004;  2(11) 1954-1959
  CrossrefPubMedGoogle Scholar
• 5 Spronk H M, Dielis A W, Panova-Noeva M et al.. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?.  Thromb Haemost. 2009;  101(6) 1156-1162
  PubMedGoogle Scholar
• 6 Enjeti A K, Lincz L F, Scorgie F E, Seldon M. Circulating microparticles are elevated in carriers of factor V Leiden.  Thromb Res. 2009;  , December 17 (Epub ahead of print)
  PubMedGoogle Scholar
• 7 Kluft C, Meijer P, Kret R et al.. Lipids, microparticles and coagulation factors as determinants of lag phase and rate of thrombin generation in plasma.  J Thromb Haemost. 2007;  5(Suppl 2) PM114
  PubMedGoogle Scholar
• 8 van Beers E J, Schaap M C, Berckmans R J CURAMA study group et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease.  Haematologica. 2009;  94(11) 1513-1519
  CrossrefPubMedGoogle Scholar
• 9 Gerotziafas G T, Depasse F, Busson J, Leflem L, Elalamy I, Samama M M. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay.  Thromb J. 2005;  3 16
  CrossrefPubMedGoogle Scholar
• 10 Joop K, Berckmans R J, Nieuwland R et al.. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.  Thromb Haemost. 2001;  85(5) 810-820
  PubMedGoogle Scholar
• 11 Scott C F, Schapira M, James H L, Cohen A B, Colman R W. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.  J Clin Invest. 1982;  69(4) 844-852
  CrossrefPubMedGoogle Scholar

Cornelis KluftPh.D. 

ECAT Foundation

P.O. Box 30, 2300 AA Leiden, The Netherlands

Email: kluft@euronet.nl